- Structure Therapeutics announced recently that it closed an oversubscribed $33 million financing round. These are the details.
Structure Therapeutics announced recently that it closed an oversubscribed $33 million financing round, which extended its $100 million Series B financing. Plus Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study of its lead type 2 diabetes and obesity program, GSBR-1290.
The funding included new investors Deep Track Capital and Piper Heartland Healthcare Capital. And the proceeds from the financing will be used to advance Structure Therapeutics’ lead programs in clinical investigation and expand application of its next generation structure-based drug discovery platform to drive innovations in G-protein coupled receptor (GPCR) targeted therapies.
Clinical Progress with GSBR-1290
Structure Therapeutics had completed dosing in a SAD Phase 1 clinical study of GSBR-1290, an orally available small molecule GLP‐1 receptor agonist being developed for the treatment of patients with type 2 diabetes mellitus and obesity. And the first-in-human Phase 1 study was conducted in 48 healthy volunteers and was designed to evaluate the safety, tolerability and pharmacokinetics of GSBR-1290. GSBR-1290 was generally well tolerated in the SAD study, with no serious adverse events reported.
GLP-1R is a validated GPCR drug target for the treatment of diabetes and obesity. And there are currently 5 marketed peptide molecules that target GLP-1R, generating aggregate worldwide sales of $13.1 billion in 2020. However, there are currently no approved oral small molecule therapies targeting GLP-1R.
Corporate Name Change
Structure Therapeutics was selected as the company’s new name to reflect its foundation in structural biology and computational design. And the company harnesses the power of these technologies to discover next-generation small molecule therapies to replace biologics and peptide therapies.
“We see significant potential for Structure Therapeutics to create and advance best-in-class, oral therapeutics for some of the most significant global health needs today. We are proud to support Structure Therapeutics as it continues to move its lead programs through clinical investigation, while also identifying new opportunities to apply its powerful technology.”
— David Kroin, Founder and Chief Investment Officer of Deep Track Capital
“Utilizing our powerful platform, the Structure Therapeutics team designed GSBR-1290 to be a biased orally available GLP-1R agonist, mitigating β-arrestin mediated internalization and desensitization of the receptor. Given its significant preclinical activity and oral availability as a small molecule, GSBR-1290 may offer a differentiated treatment option to existing GLP-1R peptide therapeutics for patients suffering from diabetes and obesity.”
— Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics
“As we continue to grow and validate our pipeline, we took the opportunity to revisit our name and connect the meaning to the backbone of our scientific approach and technology in structure-based drug discovery. We are proud to enter this new chapter with the support of our strong investor syndicate and great drug hunter team as we leverage our powerful platform to design superior small molecules to overcome limitations of biologics and peptide therapies.”
— Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics